Intensive Versus Standard Blood Pressure Control in Type 2 Diabetes: Cardiovascular and Microvascular Outcomes

Optimal blood pressure (BP) targets in type 2 diabetes mellitus (T2DM) remain uncertain, particularly following recent large-scale trials. The balance between cardiovascular protection and potential harms from intensive BP lowering continues to be debated.

This study aimed to update the evidence comparing intensive versus standard BP control in T2DM by incorporating data from the recent BPROAD trial and reassessing cardiovascular and microvascular outcomes across major randomized trials.

This meta-analysis included eight randomized controlled trials (ABCD, Mehler 2003, ABCD-2V, SANDS, INVEST, ACCORD-BP, J-DOIT3, and BPROAD), comprising a total of 25,686 participants. Intensive arms consistently achieved ~120/70 mmHg regardless of specific trial targets. Follow-up ranged 1.9-8.5 years. The primary end-point was a composite of fatal/non-fatal cardiovascular events; secondary endpoints were diabetic retinopathy, neuropathy and urine albumin excretion (UAE). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated with a random-effects model; heterogeneity was expressed as I².

Compared to standard BP control, intensive BP lowering reduced composite cardiovascular events (OR 0.88, 95% CI 0.79-0.97; I² = 17%). Retinopathy likewise fell (OR 0.84, 95% CI 0.71-0.98; I² = 0%). UAE risk declined (OR 0.82, 95% CI 0.71-0.94; I² = 62%). The analysis showed an OR of 1.48 (95% CI 1.05-2.10; P = 0.03; I² = 0%) for neuropathy, but the small sample size and wide confidence interval limit confidence in this result.

Lowering BP to approximately 120/70 mmHg, representing a more stringent target than standard control (~135/80 mmHg) is associated with modest reductions in cardiovascular events and improvements in microvascular outcomes including retinopathy and albuminuria in type 2 diabetes. While these benefits are modest and neuropathy data remain limited, the findings support consideration of lower BP targets in this population, applied thoughtfully and tailored to individual risk and tolerability.